DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
← catalyst calendarNCT07109154 · readout in 254 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
7
Country
Brazil
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-25 | actual | When the study began enrolling |
| Primary completion | 2027-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Neoplasms
Primary outcomes
what the primary-completion date above is the date OFDescribe epidemiological characteristics of patients diagnosed with NSCLC in Brazil real-world.
measured Through study completation, an average of 2 years
Describe first-line NSCLC treatment patterns in Brazil real-world.
measured Through study completation, an average of 2 years
Evaluate the concordance between the therapeutic choices and the BSCO guidelines.
measured Through study completation, an average of 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed